Presented on July 22nd, 2022.
Each month biotechnology, pharmaceutical and academic partners, large and small, working on treatments and a cure for myotonic dystrophy will sit down with our community to share their progress and answer your questions. Click here to learn more about Harmony Biosciences.
Learn more about their ongoing clinical trial, "Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1" on ClinicalTrials.gov.
Rachel Radomski, Patient Advocacy Team
As the head of Patient Advocacy, Rachel Radomski leads Harmony’s work with people living with rare diseases, their caregivers and patient advocacy organizations across the rare disease landscape, including the Myotonic Dystrophy Foundation. The Patient Advocacy team works to represent the voice of people living with a rare disease across Harmony and develops innovative solutions and programs to meet the dynamic needs of the communities Harmony serves. Rachel and her team are honored to live Harmony’s core value of keeping “patients at the heart” of everything we do at Harmony Biosciences.
Dr. Bill Jacobson, Clinical Team
William Jacobson is the Senior Director, Clinical Development at Harmony Biosciences. Dr. Jacobson is an experienced Drug Developer and Clinical Trialist, originally trained as a Neuroscientist, with almost 30 years of experience in the pharmaceutical industry. Dr. Jacobson works on strategic and tactical aspects of drug development and his current focus is on rare diseases of the Central Nervous System. He is the clinical lead on Harmony Biosciences development program in type 1 myotonic dystrophy.